These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25711516)

  • 1. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
    Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
    J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
    Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
    J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
    Stefanachi A; Hanke N; Pisani L; Leonetti F; Nicolotti O; Catto M; Cellamare S; Hartmann RW; Carotti A
    Eur J Med Chem; 2015 Jan; 89():106-14. PubMed ID: 25462231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
    J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
    Hu Q; Yin L; Hartmann RW
    J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
    Zhu W; Hu Q; Hanke N; van Koppen CJ; Hartmann RW
    J Med Chem; 2014 Sep; 57(18):7811-7. PubMed ID: 25176013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
    Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
    Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
    Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
    Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
    J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
    Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.
    Grombein CM; Hu Q; Heim R; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 89():597-605. PubMed ID: 25462268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.
    Lucas S; Negri M; Heim R; Zimmer C; Hartmann RW
    J Med Chem; 2011 Apr; 54(7):2307-19. PubMed ID: 21384875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.